Staples Lag S&P 500 as Clorox, Marzetti, Nature's Sunshine Face Headwinds
Consumer staples failed to outpace the broader market over the last six months, with specific names showing structural decay in margins and growth.
The consumer staples sector has underperformed the S&P 500, which gained 14% over the past six months, while the sector remained flat. This divergence highlights a broader struggle for staples to deliver returns in a bull market, driven by inelastic demand that fails to generate upside momentum.
Three specific companies—Clorox, The Marzetti Company, and Nature’s Sunshine—exhibit fundamental weaknesses that limit their potential. According to data reviewed by GN stocks/sp500, these firms face declining sales trends, rising capital intensity, or slow organic growth that lags peer benchmarks.
Clorox Faces Margin Compression
Clorox, with a market capitalization of $10.28 billion, has experienced annual sales declines of 3.1% over the last three years. The company’s free cash flow margin dropped by 4.7 percentage points in the past year, signaling increased capital intensity as competition intensified. This shift suggests the firm is becoming less efficient in converting revenue to cash.
Organic revenue growth has missed benchmarks for two consecutive years, indicating that Clorox’s current product and pricing strategies are not resonating with consumers. At $84.93 per share, the stock trades at a forward P/E of 14.7x, a valuation that may not adequately compensate for the deteriorating operational metrics.
Marzetti Struggles With Scale
The Marzetti Company, valued at $2.76 billion, recorded annual revenue growth of just 1.6% over the last three years, a pace slower than its consumer staples peers. The company’s revenue base of $1.91 billion limits its fixed-cost leverage and distribution reach compared to larger competitors.
With a gross margin of 23.9%, Marzetti’s profitability is constrained by the commoditized nature of its bread and dip products. Trading at $101.28 per share, the stock commands a 15.3x forward P/E, a multiple that appears high relative to its modest growth trajectory and margin profile.
Nature's Sunshine Growth Slows
Nature’s Sunshine, with a market cap of $230.3 million, posted annual sales growth of 4.4% over the last three years, a figure below the typical consumer staples average. The company’s revenue base of $492 million places it at a structural disadvantage against larger rivals that benefit from economies of scale.
Forward-looking estimates suggest sales growth will decelerate further to 2.8% over the next 12 months. This projected slowdown in demand indicates that the company’s recent performance may not be sustainable, posing a risk to future earnings stability.
